Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ambrx Biopharma, Inc. - Common Stock (NY: AMAM )

N/A UNCHANGED
Last Price Updated: 7:00 PM EDT, Mar 16, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 10.66 (3)
Ask (Size) 11.24 (1)
Prev. Close 10.13
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Dividend Stocks That Are Too Good to Ignore: Q1 Edition
Here are the three dividend stocks that will never disappoint you. Buy them while they trade at a discount. 
Via InvestorPlace
3 Stocks to Buy That Are Up 200% or More in 2024
Each of these stocks up 200% in 2024 offer unique upside opportunities for investors, including equity arbitrage plays. 
Via InvestorPlace

Performance

More News

Read More
The 3 Biotech Stocks That Could Make Your February Unforgettable
Via InvestorPlace
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
From Kahn Swick & Foti, LLC
Via Business Wire
Looking Into Ambrx Biopharma's Recent Short Interest
Via Benzinga
Assessing Ambrx Biopharma: Insights From 7 Financial Analysts
Via Benzinga
Health Care Company Johnson & Johnson Announces Merger With Ambrx Biopharma
Via Benzinga
Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson
Via The Motley Fool
Johnson & Johnson Secures Complete FDA Approval For Bladder Cancer Drug Balversa, After Almost Five Years Of Accelerated Approval
Via Benzinga
Exposures Product Safety
Johnson & Johnson's Q4 Earnings: Spotlight On Dividend Security Following Kenvue Split, Legal Costs, Acquisitions
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
Via Talk Markets
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
Via Investor's Business Daily
Topics ETFs
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
From Kahn Swick & Foti, LLC
Via Business Wire
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
Via FinancialNewsMedia
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
From FN Media Group LLC
Via GlobeNewswire
Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results
Via Benzinga
Topics Stocks
Exposures US Equities
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
Via InvestorPlace
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal
Via Benzinga
US Stocks Mixed; Nasdaq Jumps Over 100 Points
Via Benzinga
Topics Stocks
Exposures US Equities
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
Via Investor's Business Daily
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.